Last reviewed · How we verify

Intravenous oxytocin infusion — Competitive Intelligence Brief

Intravenous oxytocin infusion (Intravenous oxytocin infusion) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Neurohypophyseal hormone. Area: Obstetrics.

phase 3 Neurohypophyseal hormone Oxytocin receptor (OXTR) Obstetrics Small molecule Live · refreshed every 30 min

Target snapshot

Intravenous oxytocin infusion (Intravenous oxytocin infusion) — Tel-Aviv Sourasky Medical Center. Oxytocin is a neurohypophyseal hormone that binds to oxytocin receptors to stimulate uterine contractions and promote milk letdown during lactation.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Intravenous oxytocin infusion TARGET Intravenous oxytocin infusion Tel-Aviv Sourasky Medical Center phase 3 Neurohypophyseal hormone Oxytocin receptor (OXTR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Neurohypophyseal hormone class)

  1. Tel-Aviv Sourasky Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Intravenous oxytocin infusion — Competitive Intelligence Brief. https://druglandscape.com/ci/intravenous-oxytocin-infusion. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: